STAT

JULY 17, 2024

For scientists and medical professionals well versed in the safety and effectiveness of vaccines, it is often too easy to write off the concerns of people who fear them, or feel they have been injured by them. But vaccine expert Kizzmekia S. Read the rest…

Vaccines 123

Vaccines 123

Drug Topics

MARCH 13, 2024

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

Vaccines 201

Vaccines Communication 201

Pharmacy Times

JULY 23, 2024

Focusing on the preparation of RSV vaccines, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides detailed insights on the differences between the adjuvanted and nonadjuvanted vaccines.

Vaccines 65

Vaccines 65

Pharmacy Times

JULY 25, 2024

Despite the century-long period of virus evolution, 6 of the 11 primates that received a cytomegalovirus-expressed flu vaccine survived the exposure to H5N1 flu.

Vaccines 117

Vaccines 117

Drug Topics

JANUARY 18, 2024

In 2023, the FDA approved six vaccines, including 2 for respiratory syncytial virus (RSV), and the first vaccine to prevent the mosquito-borne virus chikungunya.

Vaccines 187

Vaccines FDA 187

Drug Topics

JUNE 18, 2024

The vaccine covers 8 serotypes not currently covered by any FDA-approved pneumococcal vaccines.

Vaccines 200

Vaccines FDA 200

STAT

MAY 13, 2024

The number of children who received their routine vaccinations declined during the pandemic, so public health officials have been focusing on getting kids back up to date. They found that adult vaccination programs paid for themselves many times over, returning up to 19 times the initial investment in societal benefits.

Vaccines 141

Vaccines Immunization 141

STAT

JUNE 14, 2024

Nearly nine in 10 Americans strongly believe in the overall value of childhood vaccines. Reflecting the value communities place on them, every state and the District of Columbia require children to get vaccinated against certain diseases before they start school, including measles, mumps, polio, tetanus, whooping cough, and chickenpox.

Vaccines 138

Vaccines Immunization 138

Drug Topics

APRIL 24, 2024

In response to historically low flu vaccine coverage rates, Kristen Thorson, PharmD, urges pharmacists to think back to their pandemic immunization efforts and “know the power of their recommendation,” to boost public protection from influenza.

Vaccines 186

Vaccines Immunization 186

STAT

JULY 3, 2024

GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control over the development of experimental mRNA-based Covid and flu vaccines, the companies said Wednesday. billion ($1.1 billion) in future payments if certain milestones are hit. billion ($1.1 Read the rest…

Vaccines 119

Vaccines 119

pharmaphorum

MAY 30, 2024

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.

Vaccines 144

Vaccines 144

STAT

JULY 17, 2024

Vaccination lowers the chance of developing long Covid, according to a large new study that also found that the risk of serious complications has diminished but not disappeared as new coronavirus variants emerged. Read the rest…

Vaccines 145

Vaccines 145

Drug Topics

NOVEMBER 24, 2023

Study authors recommend that healthcare personnel consider prioritizing influenza vaccination for patients with recent cardiovascular diseases (CVDs) in light of new evidence.

Vaccines 232

Vaccines 232

Drug Topics

JANUARY 5, 2024

A model showed that if a vaccine coverage of 66% were achieved—similar to flu vaccination coverage—it could have a budget impact of $6.48 billion over the first RSV season.

Vaccines 198

Vaccines 198

Drug Topics

DECEMBER 24, 2023

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

Vaccines 196

Vaccines Immunization 196

STAT

JANUARY 25, 2024

A historic new study out of Scotland shows the real-world impact of vaccines against the human papillomavirus: The country has detected no cases of cervical cancer in women born between 1988-1996 who were fully vaccinated against HPV between the ages of 12 and 13.

Vaccines 145

Vaccines 145

Drug Topics

MAY 31, 2024

Researchers addressed the association between COVID-19 vaccination status and incidents of post-COVID condition.

Vaccines 187

Vaccines 187

Drug Topics

JANUARY 10, 2024

The estimated efficacy of the vaccine against documented infection for children and adolescents during the Omicron wave was 74.3% and 85.5%, respectively.

Vaccines 219

Vaccines Documentation 219

STAT

JUNE 18, 2024

Around the world, the viral infection kills about 70,000 people a year — and since as early as 2015, groups including Gavi, the Vaccine Alliance, have had plans to shore up vaccine efforts to reduce the number. On Thursday, Gavi announced a plan to expand global access to human rabies vaccines, reaching over 50 countries.

Vaccines 116

Vaccines 116

Drug Topics

JUNE 10, 2024

The vaccine, mRNA-1083, elicited noninferior responses vs individual COVID-19 and flu vaccinations.

Vaccines 154

Vaccines 154

The Guardian - Pharmaceutical Industry

MAY 7, 2024

Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or supplied AstraZeneca has begun the worldwide withdrawal of its Covid-19 vaccine due to a “surplus of available updated vaccines” that target new variants of the virus.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies 111

STAT

JUNE 17, 2024

The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older.

Vaccines 145

Vaccines FDA Hospitals 145

Drug Topics

JULY 9, 2024

Researchers are evaluating the safety, tolerability, and immunogenicity of shingles vaccine candidate Z-1018.

Vaccines 150

Vaccines 150

Drug Topics

JULY 8, 2024

Current recommendations suggest women receive the RSV vaccine between 32 and 36 weeks' gestational age.

Vaccines 145

Vaccines 145

STAT

JUNE 7, 2024

The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50. Arexvy, which was the first RSV vaccine approved , now becomes the first to be available to adults under the age of 60 who are not pregnant.

Vaccines 141

Vaccines FDA 141

pharmaphorum

JULY 22, 2024

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life-threatening mosquito-borne disease.

Vaccines 98

Vaccines 98

STAT

JUNE 26, 2024

Makers of RSV vaccines for older adults saw their plans to try to expand usage hit a significant hurdle on Wednesday, when an expert committee that advises the Centers for Disease Control and Prevention on vaccines recommended changes that will likely see fewer older adults qualify for insurance coverage for these products.

Vaccines 123

Vaccines Insurance Coverage Insurance Immunization 123

STAT

MAY 9, 2024

Weeks after the global public health community sounded the alarm on the shortage of cholera vaccine, the World Health Organization moved to prequalify a new cholera vaccine last month. The vaccine is a simplified version of the two existing oral vaccines, both produced by Korean vaccine manufacturer EuBiologics Co.

Vaccines 140

Vaccines 140

pharmaphorum

MAY 17, 2024

Navigating maternal vaccine trials: addressing safety, efficacy, and preterm birth risks. Insights on vaccines for pregnant women and maternal health.

Vaccines 115

Vaccines 115

STAT

MAY 10, 2024

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.     The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot.

Vaccines 145

Vaccines 145

Fierce Healthcare

JULY 23, 2024

Walgreens has received $25 million in grant funding to conduct a decentralized clinical trial assessing how well a person vaccinated against COVID-19 is protected from future infections. | The award comes from a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), embedded in the U.S.

Vaccines 107

Vaccines 107

STAT

SEPTEMBER 11, 2023

The Food and Drug Administration announced Monday that it had greenlit two   updated Covid-19 booster shots in people as young as 6 months old, triggering a process that could see the Moderna and Pfizer-BioNTech vaccines become available in doctors’ offices, clinics, and pharmacies later this week. Read the rest…

Vaccines 145

Vaccines FDA 145

Drug Topics

JULY 18, 2024

All participants in the phase 3 clinical trial have completed their primary vaccination series.

Vaccines 112

Vaccines 112

Fierce Pharma

JUNE 26, 2024

The respiratory syncytial virus (RSV) vaccine showdown already saw a shakeup last month with a new competitor in Moderna’s mRESVIA. | The vaccines are now recommended for adults aged 75 years and older and those aged 60 to 74 with a higher risk of severe disease. Previously, all adults aged 60 and older were advised for vaccination.

Vaccines 106

Vaccines Immunization 106

Pharmaceutical Technology

JUNE 17, 2024

1 version of its Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above. Novavax has sought US FDA approval for an updated JN.1

Vaccines 145

Vaccines FDA 145

Hospital Pharmacy Europe

JULY 26, 2024

The shingles vaccine that has been used in the NHS since last year is associated with a reduced risk of dementia, researchers have reported. A study of more than 200,000 adults before and after the US switched from Zostavax to the Shingrix vaccine found at least a 17% reduction in dementia diagnoses.

Vaccines 52

Vaccines Immunization Hospitals 52

pharmaphorum

JULY 3, 2024

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID-19 jabs.

Vaccines 113

Vaccines 113